Answers are grounded in this paper and cite their sources.
This review highlights the expanding landscape of biologic therapies targeting PCSK9, apoC3, ANGPTL3, and Lp(a) for the management of lipid disorders.
Inhibition of PCSK9 remains an attractive target. In addition to the currently available monoclonal antibodies (mAbs) and small interfering RNA (siRNA), new mAbs and the adenectin lerodalcibep are promising therapies. The antisense oligonucleotide (ASO) and siRNA inhibitors of apoC3 and ANGPTL3 are effective in severe hypertriglyceridemia and homozygous familial hypercholesterolemia, respectively, and may prove to have wider applications. ASO and siRNA inhibitors of Lp(a) are currently in cardiovascular outcome studies.
No takes yet. Share an insight, caveat, or question.
Brian Tomlinson (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: